Holen Sie sich die Stockscreener-App
0.71
1.45%
0.0004
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt XAIR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.7096
Offen:
$0.7096
24-Stunden-Volumen:
161.79K
Relative Volume:
0.02
Marktkapitalisierung:
$7.48M
Einnahmen:
$6.92M
Nettoeinkommen (Verlust:
$-32.03M
KGV:
-0.131
EPS:
-5.4201
Netto-Cashflow:
$-22.13M
1W Leistung:
+7.08%
1M Leistung:
-11.00%
6M Leistung:
-71.20%
1J Leistung:
+197.97%
1-Tages-Spanne:
$0.70
$0.7384
1-Wochen-Bereich:
$0.651
$0.801
52-Wochen-Spanne:
$0.1521
$4.78
Beyond Air Inc Stock (XAIR) Company Profile
Firmenname
Beyond Air Inc
Sektor
Branche
Telefon
516-665-8200
Adresse
900 STEWART AVENUE, GARDEN CITY, NY
Compare XAIR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XAIR
Beyond Air Inc
|
0.71 | 7.47M | 6.92M | -32.03M | -22.13M | -5.4201 |
ABT
Abbott Laboratories
|
102.15 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.19 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.53 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.07 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Beyond Air Inc Stock (XAIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Eingeleitet | D. Boral Capital | Buy |
| 2024-06-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-28 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-28 | Eingeleitet | Truist | Buy |
| 2019-10-22 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Beyond Air Inc Aktie (XAIR) Neueste Nachrichten
XAIR SEC FilingsBeyond Air Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Price performance - Yahoo Finance Australia
Beyond Air Expands Commercial Access for LungFit PH through a Purchasing Agreement with a Top 3 National Group Purchasing Organization - MarketScreener
Beyond Air secures GPO deal expanding hospital access to LungFit By Investing.com - Investing.com India
Beyond Air, Inc. Announces CEO Transition: Robert Goodman Appointed to Accelerate LungFit PH Commercial Growth 12 - Minichart
XAIR Stock Price, Quote & Chart | BEYOND AIR INC (NASDAQ:XAIR) - ChartMill
Beyond Air Expands Commercial Access for LungFit PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) - Bitget
Beyond Air, Inc. (XAIR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beyond Air Names Robert Goodman as New CEO - TipRanks
Beyond Air's Steven A. Lisi resigns as CEO; Robert Goodman named CEO - TradingView
[8-K] Beyond Air, Inc. Reports Material Event - Stock Titan
Beyond Air secures GPO deal expanding hospital access to LungFit - Investing.com
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) - The Manila Times
Nearly 2,000 more hospitals can buy Beyond Air's tankless nitric oxide system - Stock Titan
Beyond Air CEO Steve Lisi resigns, Robert Goodman appointed successor - MSN
Fed Watch: Will Beyond Air Inc outperform the market in YEAR2026 Growth vs Value & Community Trade Idea Sharing - baoquankhu1.vn
Beyond Air CEO Steve Lisi resigns, Robert Goodman named successor By Investing.com - Investing.com Australia
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO - The Manila Times
Beyond Air stock sees CEO change as BTIG maintains Neutral rating - au.investing.com
Beyond Air stock sees CEO change as BTIG maintains Neutral rating By Investing.com - Investing.com South Africa
Beyond Air Names Robert Goodman, Chief Comml Officer, as CEO >XAIR - Moomoo
Beyond Air CEO Steve Lisi resigns, Robert Goodman named successor - Investing.com
Press Release: Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO - Moomoo
Beyond Air swaps CEOs as it pushes wider LungFit PH rollout - Stock Titan
Signal Recap: Is Beyond Air Inc showing insider buyingMarket Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Earnings Risk: Will Beyond Air Inc stock benefit from M AWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Beyond Air appoints Duke Drewell as interim CFO - MSN
Form 8K Beyond Air Inc For: 15 January - Investing.com
Beyond Air, Inc. Trade Ideas — GETTEX:48L0 - TradingView
Beyond Air (XAIR) Retains 'Buy' Rating with $10 PT by D. Boral C - GuruFocus
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial - The Manila Times
Beyond Air (XAIR) Sees Promising Phase 1 Trial Results for Cance - GuruFocus
High-dose nitric oxide shot shows early activity in small cancer trial - Stock Titan
Beyond Air at Life Sciences Forum: Strategic Innovations in Medical Devices - Investing.com Canada
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
XAIR: Second-generation nitric oxide system targets global growth and improved hospital adoption - TradingView
Beyond Air to Participate in the 38th Annual Roth Conference in March - The Manila Times
Beyond Air terminates NeuroNOS sale talks with XTL Biopharmaceuticals By Investing.com - Investing.com Canada
Beyond Air terminates NeuroNOS sale talks with XTL Biopharmaceuticals - Investing.com South Africa
XTL Biopharmaceuticals (NASDAQ: XTLB) NeuroNOS deal LOI expires with Beyond Air - Stock Titan
Beyond Air (XAIR) Buy Rating Reaffirmed by D. Boral Capital | XA - GuruFocus
Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - Bitget
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - The Manila Times
Beyond Air drops NeuroNOS sale, rethinks neurological and cancer plans - Stock Titan
XTL Biopharmaceuticals Ltd. cancelled the acquisition of 85% stake in NeuroNos Limited from Beyond Air, Inc.. - marketscreener.com
New Highs: Is Beyond Air Inc stock a falling knife or bargain buy2025 Biggest Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Finanzdaten der Beyond Air Inc-Aktie (XAIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):